Patent · US Active

Lung cancer diagnosis

US11137402B2 · kind B2 · utility

0Cited by
0References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 5, 2014
Grant dateOct 5, 2021
Priority date
Expiry dateFeb 5, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K14/47
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The present invention relates to methods for detecting antibodies, methods for diagnosing lung cancer and kits for lung cancer diagnosis. The methods of the invention are based on a blood or serum sample of a subject. According to a preferred embodiment, the invention uses a combination of different peptides comprising an amino acid stretch of BARD1, short peptides and/or larger fragments thereof. In preferred embodiments, the methods of the invention comprise measuring the amount of autoimmune antibodies in the sample binding to each of the different peptides and applying a statistically determined assessment for making the diagnosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.